Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ps318
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
ps318 is a small molecule compound that has been studied in preclinical pharmacokinetic, pharmacodynamic, and toxicity models. It is not an approved pharmaceutical drug and does not appear to have reached clinical development. In preclinical studies, ps318 exhibited low gut permeability as assessed by the in-vitro Caco-2 cell model. A single oral dose pharmacokinetic study conducted on healthy mice was performed to evaluate its properties[8]. No further information regarding its mechanism of action, therapeutic indication, or developer is available from current sources.
Beyond the preview
Go deeper on ps318.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ps318.